Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant fibroblast growth factor
- Development stage
- Preclinical
- Lead developer
- Republican Research and Practical Center of Transfusion and Medical Biotechnologies
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Recombinant fibroblast growth factor (specifically FGF-2) is a recombinant protein therapeutic being developed by the Republican Research and Practical Center of Transfusion and Medical Biotechnologies in Belarus. It acts as an agonist of the fibroblast growth factor receptor (FGFR) family, initiating intracellular signaling cascades that promote cell survival, proliferation, and migration. These biological processes are essential for tissue repair and angiogenesis. The candidate is currently in preclinical development, with primary indications focused on accelerating wound healing and facilitating tissue regeneration in regenerative medicine applications.
- Other names
- FGF-2FGF2FGF 2basic fibroblast growth factorbFGFrhFGF-2rhFGF2rhFGF 2recombinant human fibroblast growth factor
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))FGFR3 (Fibroblast growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on recombinant fibroblast growth factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant fibroblast growth factor.